论文部分内容阅读
目的:比较国产与进口瑞格列奈联合二甲双胍缓释片治疗2型糖尿病的成本及效果,为临床提供经济有效的治疗方案。方法:选取我院收治的90例2型糖尿病作为研究对象,分为2组,A组46例给予国产瑞格列奈联合二甲双胍缓释片、B组44例给予进口瑞格列奈联合二甲双胍缓释片进行治疗,观察疗效和降糖费用,采用药物经济学中的成本-效果分析法(CEA)进行分析。结果:2组给药方案治疗2型糖尿病的效果相近,但进口药物组使用的费用比国产组明显升高。结论:国产药物组比进口药物组具有较好的成本-效果比,是一种经济有效的2型糖尿病治疗方案。
OBJECTIVE: To compare the cost and effect of domestic and imported repaglinide with metformin sustained-release tablets in the treatment of type 2 diabetes, and to provide a cost-effective treatment for clinical practice. Methods: Totally 90 type 2 diabetic patients treated in our hospital were divided into two groups. Group A received 46 cases of domestic repaglinide and metformin sustained-release tablets, and group B received 44 cases of imported repaglinide combined with metformin The tablets were treated and observed for efficacy and hypoglycemic costs, using cost-effectiveness analysis (CEA) in pharmacoeconomics. Results: The effects of two groups of drug regimens on type 2 diabetes were similar, but the cost of imported drug group was significantly higher than that of the domestic group. Conclusion: The domestic drug group has a better cost-effect ratio than the imported drug group and is a cost-effective treatment for type 2 diabetes.